Entrada Therapeutics, Inc. (TRDA) income statement
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$4.96−0.04 (-0.80%)
Close on Nov 17, 2026Market cap $193.13MP/E –Yield –
Entrada Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -3767.1%
- Net margin
- -3537.7%
- Return on equity, FY2025
- -39.1%
Financial strength
- Current ratio
- 10.89
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 464.6%
Valuation
- P/E ratio
- –
- Price to sales
- 41.21
- Price to book
- 0.83
- Dividend yield
- –
See a number that looks wrong?